Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
Establishment of In-House Facility and Acquisition of License for Packaging, Labeling and Storage of Regenerative Medicine Products
Joint Research Agreement for SB623 Targeting Alzheimer’s-Type Dementia
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
Notice regarding appointment of new corporate officers
Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
Keizo Nakada to Join SanBio as Corporate Officer and Head of Production
Andrew Liu to Join SanBio as Chief Strategy Officer
« 前ページへ 次ページへ »
